GPR40 AgoPAMs were first described by Luo as a potential therapy to ameliorate two of the major hormonal deficiencies in type 2 diabetes through the stimulation of insulin and GLP-1 secretion [1]. The gene discussed is INS; the disease is type 2 diabetes mellitus.